Abstract
Two decades have passed since the paradigm-changing discovery in 1994 that mutations in the ob gene (aka lep) lead to murine morbid obesity. The OB receptor (aka lepr) and natural ligand, leptin, were identified the following year. Early proof-of-concept studies in rodents and humans with homozygous ob mutations subsequently heralded the possibility that exogenously administered leptin might prove a useful therapeutic in obese humans with a normal leptin gene. Unlike the low or absent leptin blood levels observed in the presence of ob mutations, most obese subjects have relatively high circulating leptin levels, a finding suggesting that the majority of people with excess adiposity are insensitive to the hormone’s actions in vivo. Two forms of leptin were developed for proof-of-concept human studies, recombinant methionyl leptin (metreleptin), and pegylated recombinant human leptin (PEG-OB). Both the pivotal metreleptin and PEG-OB randomized double-blind placebo-controlled studies showed modest but statistically significant weight loss in overweight and obese subjects at relatively high subcutaneously administered doses. A wide range of secondary outcomes were evaluated, although most reported studies were post-hoc analyses and not designed to specifically test a selective leptin effect. While exogenously administered leptin safely promotes weight loss in obese humans with a normal leptin gene, efficacy is modest and thus little clinical value can be ascribed to this treatment approach across the population as a whole. Strategies for overcoming the insensitivity to leptin’s actions in the presence of excess adiposity are needed for this hormonal mechanism to prove useful as a clinical therapeutic.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- BMI:
-
Body mass index
- CSF:
-
Cerebrospinal fluid levels
- Cmax :
-
Peak concentrations
- IGF:
-
Insulin-like growth factor
- OB-R:
-
Leptin receptor
- PEG:
-
Polyethylene glycol
- PEG-OB protein:
-
Pegylated recombinant native human leptin
- REE:
-
Resting energy expenditure
- r-metHu-Leptin and metreleptin:
-
Recombinant methionyl leptin
- RQ:
-
Respiratory quotient
- SC:
-
Subcutaneous
- VLED:
-
Very-low energy diet
References
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–32. PubMed PMID: 7984236, Epub 1994/12/01. eng.
Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269(5223):543–6. PubMed PMID: 7624777, Epub 1995/07/28. eng.
Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, et al. Identification and expression cloning of a leptin receptor OB-R. Cell. 1995;83(7):1263–71. PubMed PMID: 8548812, Epub 1995/12/29. eng.
Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387(6636):903–8. PubMed PMID: 9202122, Epub 1997/06/26. eng.
Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341(12):879–84. PubMed PMID: 10486419, Epub 1999/09/16. eng.
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292–5. PubMed PMID: 8532024, Epub 1996/02/01. eng.
Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999;282(16):1568–75. PubMed PMID: 10546697, Epub 1999/11/05. eng.
Hukshorn CJSW, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab. 2000;85(11):4003–9.
Varnerin JP, Smith T, Rosenblum CI, Vongs A, Murphy BA, Nunes C, et al. Production of leptin in Escherichia coli: a comparison of methods. Protein Expr Purif. 1998;14(3):335–42. PubMed PMID: 9882567, Epub 1999/01/12. eng.
Chan JL, Wong SL, Orlova C, Raciti P, Mantzoros CS. Pharmacokinetics of recombinant methionyl human leptin after subcutaneous administration: variation of concentration-dependent parameters according to assay. J Clin Endocrinol Metab. 2007;92(6):2307–11. PubMed PMID: 17405837, Epub 2007/04/05. eng.
Chan JL, Wong SL, Mantzoros CS. Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity. Clin Pharmacokinet. 2008;47(11):753–64. PubMed PMID: 18840030, Pubmed Central PMCID: 2737404, Epub 2008/10/09. eng.
Fujioka K, Patane J, Lubina J, Lau D. CSF leptin levels after exogenous administration of recombinant methionyl human leptin. JAMA. 1999;282(16):1517–8. PubMed PMID: 10546689, Epub 1999/11/05. eng.
Zelissen PM, Stenlof K, Lean ME, Fogteloo J, Keulen ET, Wilding J, et al. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2005;7(6):755–61. PubMed PMID: 16219020, Epub 2005/10/13. eng.
Hukshorn CJ, Westerterp-Plantenga MS, Saris WH. Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men. Am J Clin Nutr. 2003;77(4):771–6. PubMed PMID: 12663271, Epub 2003/03/29. eng.
Hukshorn CJ, Menheere PP, Westerterp-Plantenga MS, Saris WH. The effect of pegylated human recombinant leptin (PEG-OB) on neuroendocrine adaptations to semi-starvation in overweight men. Eur J Endocrinol. 2003;148(6):649–55. PubMed PMID: 12773137, Epub 2003/05/30. eng.
Lejeune MP, Hukshorn CJ, Saris WH, Westerterp-Plantenga MS. Effect of dietary restraint during and following pegylated recombinant leptin (PEG-OB) treatment of overweight men. Int J Obes Relat Metab Disord. 2003;27(12):1494–9. PubMed PMID: 14634680, Epub 2003/11/25. eng.
Hukshorn CJ, Lindeman JH, Toet KH, Saris WH, Eilers PH, Westerterp-Plantenga MS, et al. Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab. 2004;89(4):1773–8. PubMed PMID: 15070944, Epub 2004/04/09. eng.
Lejeune MP, Hukshorn CJ, Saris WH, Westerterp-Plantenga MS. Effects of very low calorie diet induced body weight loss with or without human pegylated recombinant leptin treatment on changes in ghrelin and adiponectin concentrations. Physiol Behav. 2007;91(2–3):274–80. PubMed PMID: 17434547, Epub 2007/04/17. eng.
O’Neil P, Rogers R, Malcolm R, Shaub R, Patane J, McCamish M. Assessment of behavioral and mood changes among obese persons receiving exogenous leptin. Obes Res. 1999;7(S1):92S.
Westerterp-Plantenga MS, Saris WH, Hukshorn CJ, Campfield LA. Effects of weekly administration of pegylated recombinant human OB protein on appetite profile and energy metabolism in obese men. Am J Clin Nutr. 2001;74(4):426–34. PubMed PMID: 11566639, Epub 2001/09/22. eng.
Shetty GK, Matarese G, Magkos F, Moon HS, Liu X, Brennan AM, et al. Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. Eur J Endocrinol. 2011;165(2):249–54. PubMed PMID: 21602313, Pubmed Central PMCID: 3159386, Epub 2011/05/24.eng.
Barazzoni R, Zanetti M, Stebel M, Biolo G, Cattin L, Guarnieri G. Hyperleptinemia prevents increased plasma ghrelin concentration during short-term moderate caloric restriction in rats. Gastroenterology. 2003;124(5):1188–92. PubMed PMID: 12730858, Epub 2003/05/06. eng.
Chan JL, Bullen J, Stoyneva V, Depaoli AM, Addy C, Mantzoros CS. Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess. J Clin Endocrinol Metab. 2005;90(3):1618–24. PubMed PMID: 15613407, Epub 2004/12/23. eng.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Heymsfield, S.B., Münzberg, H. (2015). Leptin Therapy in People with a Normal Leptin Gene. In: Dagogo-Jack, MD, S. (eds) Leptin. Springer, Cham. https://doi.org/10.1007/978-3-319-09915-6_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-09915-6_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-09914-9
Online ISBN: 978-3-319-09915-6
eBook Packages: MedicineMedicine (R0)